Corcept Therapeutics Incorporated (CORT)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
$111.62-1.05%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
QuarterlyIQ Insights · CORT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 47.3% |
| Our one-year growth estimate | diamond | 63.1% |
Growth built into the price is above our model estimate.
The price assumes 15.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Worth watching into the next print: this name operates in a high-miss-rate industry and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 4 industry peers · Company calendar date is not available
CORT — litigation filed
Dated 2026-06-03
Other Events. On May 19, 2026, Corcept Therapeutics Incorporated (the “Company”) learned that the United States Department of Justice (the “DOJ”) had filed a Notice of Election to Decline Intervention (the “Notice”) in a civil qui tam action filed against the company, captioned U.S. et al. ex rel. Stephen Elliott v. Corcept Therapeutics, Inc. , No. 17-CV-1303 (SRC) (D.N.J.). That action was initiated in February 2017, in the District Court of New Jersey, by a former employee of the Company (t…
Why it matters: Strong revenue growth would back management's guidance. It shows ongoing demand for Lifyorli.
Supportive ifQ3 revenue is over $300 million. This shows strong sales momentum.
Worry ifQ3 revenue falls below $250 million, suggesting weaker demand.
Why it matters: Changes to the incentive plan can affect how motivated management is. This can also impact how well the company performs.
Watch forAnnouncement of new performance metrics tied to the incentive plan.
Also watch forNo changes or updates to the incentive plan metrics.
Why it matters: The outcome of the lawsuit could impact the company's reputation and finances. Investors are paying close attention.
Worry ifThe DOJ declines to pursue further action, clearing the company.
Less concerning ifThe DOJ takes more action against the company, which could lead to penalties.
Why it matters: Good trial results could lead to more use of relacorilant for different cancers. This would help Corcept's cancer treatments.
Watch forBELLA trial results show a big boost in patient outcomes with relacorilant.
Also watch forBELLA trial results show no big improvement in patient outcomes.
Why it matters: The case outcome could affect Corcept's reputation and financial health.
Worry ifNo further legal actions or negative developments arise from the DOJ case.
Less concerning ifNew legal issues or bad findings come from the DOJ case affecting the company.
Why it matters: Maintaining revenue above $1.1 billion would show strong demand for Lifyorli and Korlym. This supports growth expectations.
Supportive if2026 revenue exceeds $1.1 billion as guided.
Worry if2026 revenue falls below $1.1 billion.
Why it matters: Earnings results will show how well Corcept is performing. This could affect investor confidence.
Watch forEarnings report shows revenue growth above 10% year over year.
Also watch forEarnings report shows revenue growth below 5% year over year.
Why it matters: A slowdown in sector growth could impact Corcept's performance. It signals broader challenges.
Worry ifSector revenue growth falls below its median of 10%.
Less concerning ifSector revenue growth remains above its median.
Why it matters: The FDA's decision will affect relacorilant's market and Corcept's growth. Approval could raise revenues a lot.
Supportive ifFDA approves relacorilant for Cushing's syndrome. This shows it is safe and works well.
Worry ifFDA rejects the NDA or requests further data, delaying approval.
Why it matters: Results could show that miricorilant works for metabolic dysfunction. This would affect Corcept's growth plans.
Watch forThe MONARCH trial had good results. It tested miricorilant in patients with liver disease.
Also watch forNegative results from the MONARCH trial or delays in reporting.
Why it matters: If this guidance is exceeded, it would show strong growth for Corcept's products. This is especially true for Lifyorli.
Supportive if2026 Q3 revenue exceeds $1.1 billion.
Worry if2026 Q3 revenue falls below $1.1 billion.
Why it matters: Results from this trial could prove miricorilant works and add to Corcept's treatment options.
Watch forMONARCH trial results show clear improvement in patients with MASH.
Also watch forMONARCH trial results show no clear improvement in patients with MASH.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$174 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $471 loss on $10,000 · 4.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,440 loss on $10,000 · 64.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.